Arcus Biosciences, Inc. (RCUS)
29.81
+0.10
(+0.34%)
USD |
NYSE |
Sep 02, 16:00
29.81
0.00 (0.00%)
After-Hours: 17:49
Arcus Biosciences Cash from Operations (TTM) : -474.00M for June 30, 2026
Cash from Operations (TTM) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Cash from Operations (TTM) Data
| Date | Value |
|---|---|
| June 30, 2026 | -474.00M |
| March 31, 2026 | -488.00M |
| December 31, 2025 | -482.00M |
| September 30, 2025 | -462.00M |
| June 30, 2025 | -339.00M |
| March 31, 2025 | -300.00M |
| December 31, 2024 | -170.00M |
| September 30, 2024 | -158.00M |
| June 30, 2024 | -247.00M |
| March 31, 2024 | -210.00M |
| December 31, 2023 | -306.00M |
| September 30, 2023 | -287.74M |
| June 30, 2023 | -305.70M |
| March 31, 2023 | -314.00M |
| December 31, 2022 | 438.00M |
| September 30, 2022 | 445.64M |
| Date | Value |
|---|---|
| June 30, 2022 | 472.84M |
| March 31, 2022 | 464.15M |
| December 31, 2021 | -256.17M |
| September 30, 2021 | -243.95M |
| June 30, 2021 | 26.07M |
| March 31, 2021 | 76.13M |
| December 31, 2020 | 111.17M |
| September 30, 2020 | 151.58M |
| June 30, 2020 | -92.08M |
| March 31, 2020 | -87.90M |
| December 31, 2019 | -73.46M |
| September 30, 2019 | -71.10M |
| June 30, 2019 | -55.46M |
| March 31, 2019 | -46.59M |
| December 31, 2018 | -43.00M |
| September 30, 2018 | -60.95M |
Cash From Operations Definition
Represents the net cash flow from the company's business operations.
Cash from Operations (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Operations (TTM) Benchmarks
| Halozyme Therapeutics, Inc. | 818.60M |
| AVITA Medical, Inc. | -24.71M |
| Iovance Biotherapeutics, Inc. | -264.18M |
| Editas Medicine, Inc. | -119.86M |
| Recursion Pharmaceuticals, Inc. | -350.48M |